burroughs wellcome co. begins u.s. clinical trial program with

CDC HIV/AIDS/Viral Hepatitis/STD/TB Prevention News Update Burroughs Wellcome Co. Begins U.S. Clinical Trial Program with
March 1, 1995

PR Newswire (02/28/95) On Tuesday, Vertex Pharmaceuticals Inc. and Burroughs Wellcome Co. announced the commencement of a Phase I clinical trial for VX-478 in the United States. The trial is a dose escalation trial designed to test the tolerability, pharmacokinetics, and oral bioavailability of VX-478, an orally administered protease inhibitor for the treatment of HIV infection and AIDS that was designed by Vertex. The study is the first in an international clinical development program for VX-478 being undertaken by Burroughs Wellcome, Kissei Pharmaceutical Co., and Vertex. Burroughs Wellcome and Kissei will use the results of the trial to develop trials to determine the safety and anti-HIV efficacy of VX-478 alone and in combination with reverse transcriptase inhibitors. "The Burroughs Wellcome- sponsored clinical program and the Kissei studies planned for Japan are part of an effort that is both extensive and designed to generate data rapidly on VX-478," said Dr. Joshua Boger, President and CEO of Vertex. "We and our partners believe that the pharmaceutical attributes of VX-478 make it a very promising drug candidate for the treatment of AIDS and HIV infection."

Most Read: Latest Added Related Topics White House LGBT Conference on HIV/AIDS UNITED STATES: White House in Atlanta: LGBT AIDS Conference No more single-theme conferences: global HIV prevention conference planned FHI 360 Senior Scientist Lut Van Damme Receives International Microbicide Conference Lifetime Achievement Award Equatorial Guinea Ministry of Health and Social Welfare and UNICEF Refute Erroneous AIDS Prevalence Figures Photographs from A Day with HIV Now Online Bulgaria urges Libya to investigate AIDS nurses case Engineers enter fight against AIDS in Africa Gilead’s Complera® Non-Inferior to Atripla® Among Treatment-Naive HIV Patients UN chief Ban calls world leaders to end Aids by 2020 CANADA: Health Officials in St. John's N.L., Inform 50 People of Tuberculosis Risk OHIO: Cleveland LGBT Community Center Offers Free Support Groups and HIV, STD Testing: The Frugal Patient CALIFORNIA: Local Church Sends HIV/AIDS Care Packs to Swaziland NEVADA: Clinics Offer Low-Cost Care for those Lacking Insurance CONNECTICUT: At Hartford Public High School, A Day Reserved for 'Healthy Relationships' ITALY: HIV Is No Barrier to Successful Liver Transplant for Cancer Treatment KENYA: Kenya Launches Universal HPV Vaccine Access to Youths UNITED STATES: Navajo Confront an Increase in New H.I.V. Infections Uganda: HIV Vaccine Trials to Start in July Uganda: Remembering Those Killed By HIV/AIDS (International AIDS Candlelight Memorial) Uganda: HIV Vaccine Trials to Start in July Experimental Gilead drug effective in early-stage leukemia trial Sangamo BioSciences Presents Clinical Data Demonstrating HIV Reservoir Reduction in HIV-Infected Subjects Treated with ZFP Therapeutic(R), SB-728-T CANADA: Program Allows Teens to Text Their Sex Questions Varsities danger zones as US cuts AIDS funds THE BAHAMAS: U.S. Charge d'Affaires Presents $14,000 to Bahamian Organizations to Promote HIV/AIDS Awareness 2012 US medicine sales show shifts by drug type Simpler ARV treatment begins in Eastern Cape US researchers develop new tool in HIV vaccine fight MET-Rx® Launches MET-Rx® Cares U.S. Charitable Giving Program
Copyright © 1995 -CDC Prevention News Update, Publisher. All rights reserved to Information, Inc., Bethesda, MD. The CDC National Center for HIV, STD and TB Prevention provides the following information as a public service only. Providing synopses of key scientific articles and lay media reports on HIV/AIDS, other sexually transmitted diseases and tuberculosis does not constitute CDC endorsement. This daily update also includes information from CDC and other government agencies, such as background on Morbidity and Mortality Weekly Report (MMWR) articles, fact sheets, press releases and announcements. Reproduction of this text is encouraged; however, copies may not be sold, and the CDC HIV/STD/TB Prevention News Update should be cited as the source of the information. Contact the sources of the articles abstracted below for full texts of the articles. Information in this article was accurate in March 1, 1995. The state of the art may have changed since the publication date. This material is designed to support, not replace, the relationship that exists between you and your doctor. Always discuss treatment options with a doctor who specializes in treating HIV.